<DOC>
	<DOCNO>NCT02945150</DOCNO>
	<brief_summary>Proof concept , open-label single center study donation HCV positive kidney HCV negative patient , preemptive , interventional treatment prevent HCV transmission upon transplantation .</brief_summary>
	<brief_title>Preemptive Treatment With Grazoprevir Elbasvir Donor HCV Positive Recipient HCV Negative Kidney Transplant</brief_title>
	<detailed_description>The study objective determine administration grazoprevir elbasvir ( without ribavirin ) 12-16 week kidney transplantation prevents spread HCV infection donor kidney know HCV genotype 1 4 infection HCV negative recipient evidence negative HCV viral RNA 12 week post treatment</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>1 . Must meet MGH transplant center criterion already list isolated kidney transplant 2 . No available living kidney donor 3 . Patient ≤ 548 day accrue transplant wait time 4 . Patient chronic hemodialysis peritoneal dialysis 5 . Weight ≥ 50kg 6 . Serum ALT within normal limit 1 . AB blood type 2 . BMI &gt; 30 3 . History liver disease 4 . Pregnant nursing ( lactate ) woman 5 . Cardiomyopathy pulmonary hypertension 6 . Positive crossmatch positive donor specific antibodies 7 . HIV positive 8 . HCV RNA positive 9 . HBV surface antigen positive 10 . Any contraindication kidney transplant per MGH center protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>hemodialysis</keyword>
	<keyword>peritoneal dialysis</keyword>
	<keyword>renal failure</keyword>
	<keyword>kidney transplant</keyword>
</DOC>